EPISODE · Aug 3, 2023 · 28 MIN
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease Donanemab in Early Symptomatic Alzheimer Disease
Embed this episode
NOW PLAYING
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
0:00
28:48
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of JAMA Clinical Reviews?
This episode is 28 minutes long.
When was this JAMA Clinical Reviews episode published?
This episode was published on August 3, 2023.
Can I download this JAMA Clinical Reviews episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!